ReviewPharmaceutics2023
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06483685 (Global Insights Into Therapeutic Radiopharmaceuticals Safety), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Global Insights Into Therapeutic Radiopharmaceuticals Safety: A Comprehensive Analysis From the WHO Pharmacovigilance Database (RADIANTS)
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Atomic degradation: chemical design strategies and immunotherapeutic mechanisms of radio-PROTACs.Annals of nuclear medicine · 2026Review
- Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026Review
- Optimization of Gravity Infusion Protocols forPharmaceutics · 2026Article
- Dosimetry inJournal of clinical medicine · 2026Review
- Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance.Molecules (Basel, Switzerland) · 2026Review
- Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation.Molecular cancer · 2026Review
- Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics.Nanomaterials (Basel, Switzerland) · 2026Article
- 177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public.Nuklearmedizin. Nuclear medicine · 2026Article
- Drug interactions involving therapeutic radiopharmaceuticals: a systematic review.EJNMMI radiopharmacy and chemistry · 2026Review
- Review
- Global insights into [Scientific reports · 2026Article
- Global clinical trial activity in metastatic castration-resistant prostate cancer from January 2020 to March 2026: a landscape analysis.Frontiers in oncology · 2026Review
- Compact accelerator-based production of carrier-freeEJNMMI radiopharmacy and chemistry · 2025Article
- Beyond similarities: overall survival and prognostic insights from [¹⁷⁷Lu]Lu-DOTATOC therapy in neuroendocrine tumors.European journal of nuclear medicine and molecular imaging · 2025Article
- Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment.International journal of molecular sciences · 2025Review
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- A Comprehensive Review on Novel Pathways in Cancer Treatment: Clinical Applications and Future Prospects.Current cancer drug targets · 2025Review
- Preliminary Study on Lutetium-177 and Gold Nanoparticles: Apoptosis and Radiation Enhancement in Hepatic Cancer Cell Line.Current issues in molecular biology · 2024Article
- Activity quantification and dosimetry in radiopharmaceutical therapy with reference toFrontiers in nuclear medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.